Stanley He
Get their honest, personalized take on your startup.
Sign in to pitch Stanley →At a glance
- Full Name
- Stanley He
- Title
- Angel / individual investor; formerly Chief Business Officer, RNAimmune (2020–2024); currently Global Analytics & Insights Associate Director, AstraZeneca
- Firm
- Individual / Angel (no fund vehicle); day job at AstraZeneca, prior operating role at RNAimmune
- Firm Type
- Angel Investor
- Investment Stage
- Seed (for private consumer-tech bets); also invests in publicly-listed biotech equities
- Sector Focus
- Consumer technology / SaaS (private, seed); biotechnology (public-market)
- Geographic Focus
- Primarily United States
- Location
- Bethesda, Maryland, United States
Background
Stanley He is a biotech and healthcare business-development executive who invests personally as an angel on the side. He earned a B.S. in Business Administration from Babson College and an MBA from Georgetown University's McDonough School of Business. His early career spanned operating and investment roles, including Business Development Manager at BloomSky, Project Manager at Wearable X, Business Systems Analyst at American Express, and a private-equity associate role at Principle Capital, followed by a healthcare-investment stint at Sigma Square Capital.
He moved into the RNA-therapeutics space in November 2019 as a Business Development hire at Sirnaomics, the gene-silencing biotech founded by Patrick Lu. When Sirnaomics spun out its mRNA vaccine and therapeutics unit as RNAimmune in 2020, He joined the new company as Chief Business Officer, a role he held from June 2020 until August 2024. In that capacity he was a business/contact lead during RNAimmune's early fundraising and partnership-building period (the company's seed financings and its collaboration with Codex DNA). RNAimmune itself is led by founder, President and CEO Dr. Dong Shen, MD, PhD.
Since August 2024, He has worked at AstraZeneca as Global Analytics & Insights Associate Director, based in the Bethesda, Maryland area. His investing reflects this dual background: a professional grounding in life sciences combined with a personal interest in early-stage consumer software.
Investment Thesis & Focus
- Describes himself as an "avid individual investor who focuses on publicly-listed biotech companies and seed-stage consumer tech companies." (his stated framing)
- Two distinct lanes: (1) public biotech equities — leveraging deep domain knowledge from RNAimmune/Sirnaomics/AstraZeneca; (2) private seed-stage consumer technology / SaaS — small angel checks.
- Operates as an individual angel rather than through a managed fund, so check sizes are personal-scale (typically small seed/angel tickets) rather than institutional.
- Likely values founders and teams he can evaluate through a product and business-development lens, consistent with his BD/operating background.
Notable Investments
- Taskade — AI-powered productivity, task-management and team-collaboration SaaS; a Y Combinator (S19) company. Seed-stage consumer-tech angel position.
- Outlier Collective — early-stage company listed among his angel investments (commercial products/consumer category).
- *(Aggregator data indicates roughly two disclosed private angel investments; his public-equity biotech positions are not individually disclosed.)*
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.